In short
Clinical trials investigating Saline are testing it as a control or placebo in many studies. These trials look at safety, efficacy, and other outcomes in different patient groups, such as people with COPD, cancer, infections, diabetes, and surgical patients.
Key points
- Clinical trials involving Saline are being run in many different conditions, including COPD, pneumonia, RSV, obesity, Alzheimer’s disease, cancer, diabetes, and surgery-related pain or blood loss. Most studies are Phase 2 or Phase 3, with one Phase 1 trial and one low-intervention study. Saline is usually used as a placebo or control treatment so researchers can compare results fairly. The main outcomes include immune response, survival, pain, infection risk, lung function, safety, and recovery measures. Some trials study adults, while others include children or older adults. These studies help researchers test whether the active treatments work better than Saline.
Trial overview
Across the trials provided, Saline is used mainly as a placebo or comparison treatment, not as the main study drug. The studies are testing many different treatments against Saline in areas such as lung disease, infection, cancer, diabetes, surgery, pain, and immune-related disease. Most of the trials are interventional, which means researchers assign treatments and then measure what happens.
Conditions being studied
The trials cover a wide range of conditions. These include chronic obstructive pulmonary disease (COPD), community-acquired pneumonia, respiratory syncytial virus, obesity, early symptomatic Alzheimer’s disease, pancreatic cancer, advanced chronic ischemia with risk of amputation, ovarian cancer, alpha-1 antitrypsin deficiency-associated liver disease, anal fistula, alcohol use disorder, Dupuytren disease, presymptomatic type 1 diabetes, and postoperative pain or blood loss in surgery.
Some studies focus on adults only, such as the RSV vaccine study in immunocompromised patients aged 18 years and older. Other studies include children, such as the trial in pediatric patients with presymptomatic type 1 diabetes and the study of blood loss in pediatric hip surgery.
Who can participate
Who can join depends on the disease and the study goal. Some trials recruit people with a specific illness, such as COPD, metastatic pancreatic cancer, or alpha-1 antitrypsin deficiency-associated liver disease.
Other studies recruit healthier volunteers or people in a broader group. For example, one trial includes healthy adult participants for propofol injection pain, and another includes healthy volunteers to study liraglutide effects on gut movement and hunger.
Some studies also have special target groups, such as immunocompromised patients, older adults aged 80 years and above, or children with diabetes or surgical needs.
Trial phases and study designs
The data include Phase 1, Phase 2, Phase 3, and one Low Intervention study. Phase 2 trials are common in the list and are used to look more closely at whether a treatment works and to continue safety testing. Phase 3 trials are also common and usually compare treatments in larger groups to confirm benefit and safety.
Several trials are randomized, blinded, or placebo controlled. These designs help reduce bias by making comparisons fairer between the active treatment and Saline.
Main endpoints and outcomes
The primary endpoints vary by study. Some trials measure immune response, such as changes in cytokine production in COPD or interferon-gamma response after vaccination.
Other trials measure clinical outcomes that matter to patients, including overall survival in metastatic pancreatic cancer, progression-free survival in ovarian cancer, days alive and out of hospital in pneumonia, pain scores after surgery, blood loss during surgery, and scar quality after wound healing.
Some studies focus on safety and tolerability, such as the trials in early symptomatic Alzheimer’s disease and alpha-1 antitrypsin deficiency-associated liver disease. Others measure functional change, such as walking distance, ankle/brachial index, sperm concentration, muscle strength, insulin sensitivity, or time until rescue pain medicine is needed.
Key studies using Saline
In the COPD vaccine study, Saline is part of a Phase 2 trial that compares vaccination effects on innate immune training, which means the early part of the immune system is being studied for stronger responses after stimulation. In the pneumonia study, Saline is part of a Phase 2 strategy comparing inhaled levofloxacin with standard intravenous antibiotics, and the main result is days alive and out of hospital at 14 days.
In the RSV vaccine study, immunocompromised adults receive Saline or the vaccine, and the main endpoint is the fold increase in RSV-A and RSV-B neutralizing titers, which are antibodies that can block the virus. In the pancreatic cancer trial, Saline is the placebo arm in a large Phase 3 study measuring overall survival.
In the diabetes and immune studies, Saline is used in trials that look at whether treatment can keep children in stage 1 type 1 diabetes and how many adverse events occur over time. In the surgery and pain studies, Saline is used to compare pain relief, blood loss, and nerve block effects after procedures.
What these trials mean for patients
These studies show that Saline is being used as a comparison treatment across many medical fields. The goal is not to study Saline itself as a treatment, but to see whether the active study drug or procedure works better than Saline.
For patients, this means the trial may be looking at whether a vaccine, medicine, block, infusion, or surgery-related treatment improves outcomes compared with a placebo control. The important results vary by condition, but they often include symptoms, recovery, safety, and longer-term health changes.